Brought to you by:
First patient enrolled in Disrupt BTK II study for long, calcified, below-the-knee lesions
Shockwave Medical has announced the start of the Disrupt BTK II postmarket study to assess the safety, effectiveness and optimal clinical use of the Shockwave peripheral intravascular lithotripsy (IVL) system for the treatment of calcified peripheral lesions below the knee (BTK), including some…
VIVA 2021: IVL ‘consistently’ treats real-world calcium in multiple peripheral vessel beds
An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL) performs “consistently well” across challenging peripheral vessels, lesions and subgroups of patients, Ehrin J. Armstrong, MD, medical director at Adventist Heart and Vascular Institute in…
CMS creates new codes for IVL performed below the knee
Shockwave Medical has announced that as part of the calendar year 2021 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule, the Centers for Medicare & Medicaid Services (CMS) has created four new codes for intravascular lithotripsy (IVL) procedures performed…
Intravascular lithotripsy ‘superior’ to PTA in acute procedural success out to 30 days
The DISRUPT PAD III randomized controlled trial (RCT) provides the largest level-one evidence for the treatment of heavily calcified femoropopliteal arteries, noted William Gray, MD, an interventional cardiologist at Main Line Health, Philadelphia, during the second and final late-breaking data…
Shockwave Medical announces new CMS codes for intravascular lithotripsy
Shockwave Medical has announced new Centers for Medicare & Medicaid Services (CMS) codes for intravascular lithotripsy (IVL), a procedure performed in peripheral arteries in both hospital outpatient and inpatient settings. The new Healthcare Common Procedure Coding System (HCPCS) outpatient and…